去骨瓣减压术联合最佳药物治疗对比单纯最佳药物治疗自发性严重深部幕上脑出血:一项随机对照临床试验
SWITCH 试验在 9 国 42 个卒中中心纳入 18-75 岁严重基底节或丘脑脑出血患者,随机接受去骨瓣减压术联合最佳药物治疗或单纯最佳药物治疗。因资金不足提前终止,201 例随机、197 例延迟知情同意。180 天 mRS 5-6 分比例去骨瓣减压组 44% vs 单纯药物组 58%(aRR 0.77,95%CI 0.59-1.01,p=0.057)。作者认为证据薄弱,去骨瓣减压术可能优于单纯药物。
要点
- 严重深部脑出血 180 天 mRS 5-6 分:去骨瓣减压组 44% vs 单纯药物组 58%,aRR 0.77(95%CI 0.59-1.01),未达统计学显著。
- 严重不良事件去骨瓣减压组 41% vs 单纯药物组 44%。
- 作者认为证据薄弱,去骨瓣减压术可能优于单纯药物,但结果不适用于其他部位脑出血,两组存活均伴严重残疾。
核心结论
- SWITCH 提供薄弱证据表明去骨瓣减压术联合最佳药物治疗可能优于单纯最佳药物治疗严重深部脑出血。
- 结果不适用于其他部位脑出血,两组存活均与严重残疾相关。
研究设计与样本
- 多中心、随机、开放标签、评估者盲法试验,在奥地利、比利时、芬兰、法国、德国、荷兰、西班牙、瑞典和瑞士 42 个卒中中心开展。
- 纳入 18-75 岁严重基底节或丘脑脑出血成人,随机分配去骨瓣减压术联合最佳药物治疗或单纯最佳药物治疗。
- 主要结局为 180 天改良 Rankin 量表(mRS)5-6 分,在意向治疗人群分析。
- 试验因资金不足提前终止;2014年10月6日至2023年4月4日随机 201 例,197 例延迟知情同意(去骨瓣减压联合药物 96 例,单纯药物 101 例)。
- 女性 63 例(32%),男性 134 例(68%),中位年龄 61 岁(IQR 51-68),中位血肿体积 57 mL(IQR 44-74)。
主要发现
- 180 天 mRS 5-6 分:去骨瓣减压联合药物组 42/95(44%)vs 单纯药物组 55/101(58%),aRR 0.77(95%CI 0.59-1.01),aRD -13%(95%CI -26 至 0),p=0.057。
- 符合方案分析:去骨瓣减压联合药物组 36/77(47%)vs 单纯药物组 44/73(60%),aRR 0.76(95%CI 0.58-1.00),aRD -15%(95%CI -28 至 0)。
- 严重不良事件:去骨瓣减压联合药物组 42/103(41%)vs 单纯药物组 41/94(44%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 试验因资金不足提前终止。
- 主要结局在意向治疗人群的 aRR 95%CI 上限为 1.01,aRD 95%CI 上限为 0,p=0.057,未达统计学显著。
- 作者认为证据薄弱(weak evidence)。
- 结果不适用于其他部位脑出血。
- 两组存活均与严重残疾相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is unknown whether decompressive craniectomy improves clinical outcome for people with spontaneous severe deep intracerebral haemorrhage. The SWITCH trial aimed to assess whether decompressive craniectomy plus best medical treatment in these patients improves outcome at 6 months compared to best medical treatment alone. METHODS: In this multicentre, randomised, open-label, assessor-blinded trial conducted in 42 stroke centres in Austria, Belgium, Finland, France, Germany, the Netherlands, Spain, Sweden, and Switzerland, adults (18-75 years) with a severe intracerebral haemorrhage involving the basal ganglia or thalamus were randomly assigned to receive either decompressive craniectomy plus best medical treatment or best medical treatment alone. The primary outcome was a score of 5-6 on the modified Rankin Scale (mRS) at 180 days, analysed in the intention-to-treat population. This trial is registered with ClincalTrials.gov, NCT02258919, and is completed. FINDINGS: SWITCH had to be stopped early due to lack of funding. Between Oct 6, 2014, and April 4, 2023, 201 individuals were randomly assigned and 197 gave delayed informed consent (96 decompressive craniectomy plus best medical treatment, 101 best medical treatment). 63 (32%) were women and 134 (68%) men, the median age was 61 years (IQR 51-68), and the median haematoma volume 57 mL (IQR 44-74). 42 (44%) of 95 participants assigned to decompressive craniectomy plus best medical treatment and 55 (58%) assigned to best medical treatment alone had an mRS of 5-6 at 180 days (adjusted risk ratio [aRR] 0·77, 95% CI 0·59 to 1·01, adjusted risk difference [aRD] -13%, 95% CI -26 to 0, p=0·057). In the per-protocol analysis, 36 (47%) of 77 participants in the decompressive craniectomy plus best medical treatment group and 44 (60%) of 73 in the best medical treatment alone group had an mRS of 5-6 (aRR 0·76, 95% CI 0·58 to 1·00, aRD -15%, 95% CI -28 to 0). Severe adverse events occurred in 42 (41%) of 103 participants receiving decompressive craniectomy plus best medical treatment and 41 (44%) of 94 receiving best medical treatment. INTERPRETATION: SWITCH provides weak evidence that decompressive craniectomy plus best medical treatment might be superior to best medical treatment alone in people with severe deep intracerebral haemorrhage. The results do not apply to intracerebral haemorrhage in other locations, and survival is associated with severe disability in both groups. FUNDING: Swiss National Science Foundation, Swiss Heart Foundation, Inselspital Stiftung, and Boehringer Ingelheim.
引用
- Beck J, Fung C, Strbian D, et al. Decompressive craniectomy plus best medical treatment versus best medical treatment alone for spontaneous severe deep supratentorial intracerebral haemorrhage: a randomised controlled clinical trial. Lancet. 2024. PMID: 38761811. doi:10.1016/S0140-6736(24)00702-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。